ERBB2 and breast cancer: In HR+/HER2+ BC patients, N1‐2 is significantly associated with an increased risk of BM compared with N0 (OR, 1.383; 95% CI, 1.006–1.902, p = 0.046), while the risk elevation with N3 was not significant (p > 0.05).